Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Patient-centric social media for
outcomes and pharmacovigilance
considerations: The time has come
Brian Loew
Founder & CEO...
Medical-centered JourneyPatient-centered Journey
Connected Patients
PD-L1 Immunotherapy Clinical Trial
“72 hours post first immunotherapy and feeling great with no side ef...
Patient Reported Outcomes
“Can you please share your Cosentyx side effects? Hair loss? Nausea? I have never been on a biol...
Through natural language processing of anonymized
data, we are able to uncover insights about adverse
events, medication r...
Patient-centric social
media for outcomes
and pharmacovigilance
considerations: The
time has come
Greg Powell, GSK
Digital World
Project CRAWL
Contextualization of ReAl-World Drug Use Through Social ListeningDIGITAL MEDIA AS A MAINSTREAM...
How can we listen to what patients are saying online?
Project CRAWL Overview
Contextualization of Real-World Drug Use Through Social Listening
Publically available data is coll...
Key Learning (so far)
Quantity of data
 A PEW study found that 3-4% of adult internet users have posted their experience ...
Key Learning
Drug Specific
Potentially valuable clinical insights
 ~26% of people discussing drugs will talk about
effica...
Product Complaints
Key Learning
Disease Specific
0%
20%
40%
60%
80%
100%
Percent of
patients
represented
per diagnosis
mention
CV Risk
Factor...
Limitations
Causality & veracity
Patients may not correctly assess causality. Can system be gamed?
Bias
How are people who...
Conclusion
Social Media is
an important new data
source that may offer
important clinical insights
that can potentially be...
A Patient Perspective:
Patient-centric social media for
outcomes and pharmacovigilance
considerations
Julie Flygare, JD
Fo...
Why do patients go online?
What do patients get out of being online?
Social Media v. Real Life
Thank you for your attention!
Patient-centric social media for outcomes and pharmacovigilance considerations: The time has come
Patient-centric social media for outcomes and pharmacovigilance considerations: The time has come
Upcoming SlideShare
Loading in …5
×

Patient-centric social media for outcomes and pharmacovigilance considerations: The time has come

219 views

Published on

Through the use of de-identified Big Data from online patient forums open to healthcare providers, the pharmaceutical industry may glean useful insights into both the safety of existing products as well as future needs of patients. Post-marketing safety surveillance for pharmaceuticals currently relies on data from adverse event reports to companies or regulatory authorities, medical literature, and observational databases. Together these sources provide some insight into everyday product safety or risk, but the unique insight the patients themselves can offer is also highly desirable.

Using insights from a 2016 research project involving Inspire, GlaxoSmithKline (GSK) Pharmaceuticals, and Epidemico, an innovative informatics company, we are exploring the use of social listening data for pharmacovigilance and other R&D concerns. A core question is, “What valuable insights can we glean from social listening to help improve patients’ lives—whether through improved safety, more relevant clinical trials, or research and development of new treatment options?”

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

Patient-centric social media for outcomes and pharmacovigilance considerations: The time has come

  1. 1. Patient-centric social media for outcomes and pharmacovigilance considerations: The time has come Brian Loew Founder & CEO Inspire Greg Powell Director, Safety Evaluation and Risk Management GlaxoSmithKline Julie Flygare Founder Project Sleep
  2. 2. Medical-centered JourneyPatient-centered Journey
  3. 3. Connected Patients PD-L1 Immunotherapy Clinical Trial “72 hours post first immunotherapy and feeling great with no side effects that I can feel but a surprising rather quick response (I hope) is that I have been bleeding for the last several months from the upper vaginal tumor and today no bleeding. It may start up again but for the last 18hours nothing.” ”My husband is also looking into this trial. Do you know if your tumors tested positive or negative for PD-L1?” “Yesterday I got news that my CT after chemo was complete shows increasing metastasis throughout chemo. The Dr asked me if I had heard of any clinical trials and specifically mentioned immunotherapy and as of yesterday had not heard of it. Now today, I stumble upon this gem of a conversation and see all of this wonderful info and inspiring people. Thank you for sharing your experiences, they really do help others.”
  4. 4. Patient Reported Outcomes “Can you please share your Cosentyx side effects? Hair loss? Nausea? I have never been on a biologic so not sure that insurance will cover it but I'm thinking about Cosentyx....is this a good route?.” I've been on Cosentyx for a month now and the only side effect that might be attributed to Cosentyx is a bit of fatigue the day after injection. It's been great so far. My PsO is much less and it has helped my PsA a very small amount. I have been taking Cosentyx for almost a year. My psoriasis is gone and the arthritis is almost gone. I have had no side effects at all. This drug improved my quality of life immensely. Good luck!
  5. 5. Through natural language processing of anonymized data, we are able to uncover insights about adverse events, medication routine adherence, and many others related to the patient journey and health experience.
  6. 6. Patient-centric social media for outcomes and pharmacovigilance considerations: The time has come Greg Powell, GSK
  7. 7. Digital World Project CRAWL Contextualization of ReAl-World Drug Use Through Social ListeningDIGITAL MEDIA AS A MAINSTREAM COMMUNICATION CHANNEL  38 years for radio to reach 50 million users  13 years for television to reach 50 million users  1.5 years for Facebook to reach 50 million users  85% of adults use the internet  6% of adult internet users have posted comments, questions or information about health or medical issues on a website of any kind  3-4% of adult internet users have posted their experience with health care service providers or treatments in the previous 12 months Social Media Adoption Treatment Discussion Patients’ Insights
  8. 8. How can we listen to what patients are saying online?
  9. 9. Project CRAWL Overview Contextualization of Real-World Drug Use Through Social Listening Publically available data is collected from multiple sources (Facebook, Twitter, Internet chat rooms) System filters out noise, highlights important information, and supplemental data is added (spontaneous data, etc.) Users can interactively explore the information using an easy to use interface that helps facilitate the review process
  10. 10. Key Learning (so far) Quantity of data  A PEW study found that 3-4% of adult internet users have posted their experience with health care service providers or treatments in the previous 12 months. A study completed by GSK showed 22 million potential adverse events for about 1,000 drugs (publically available Facebook and Twitter posts, English language only). For comparison, the FDA’s FAERS database has ~6 million adverse event reports since 1968. Timeliness of the data  Traditional data can lag behind (9-12 months for observational data)  Social listening data is usually available within hours from the time the person posts their comments online Geographic diversity of the data  Traditional data is US and European centric.  Three of the five largest users of the internet are Asia, Latin America/Caribbean, and Africa
  11. 11. Key Learning Drug Specific Potentially valuable clinical insights  ~26% of people discussing drugs will talk about efficacy/benefits • Time to onset, complete/partial • Within context of cost, other treatment options, access challenges • How does this improve their quality of live/average daily living  6% of people discussing drugs will seek medical advice • 50% efficacy related • 25% safety related  OTC (GSK example) • Real world benefits • Can patients effectively self-manage medical condition • How real-world use differs from the products label  Drug abuse/misuse (GSK example) • Encourage/discourage use • Best route of administration • Where they get the medication • Anticipated effects • How to combine with other drugs
  12. 12. Product Complaints
  13. 13. Key Learning Disease Specific 0% 20% 40% 60% 80% 100% Percent of patients represented per diagnosis mention CV Risk Factors Mentioned Diagnostic Tests Mentioned Duration of Disease Known Drug Therapy Discussed Type of Reporter Known Age Range Known Gender Known Country Known Forums (N = 231) Twitter (N = 420) Reddit (N = 9,097) Inspire (N = 2,911)
  14. 14. Limitations Causality & veracity Patients may not correctly assess causality. Can system be gamed? Bias How are people who post online similar/different than general population? Volume Volume of reports likely to be large. Privacy & generalizability Patient privacy expectations and fear of government oversight. Regulation unclear When is there an obligation to monitor or report?
  15. 15. Conclusion Social Media is an important new data source that may offer important clinical insights that can potentially benefit the healthcare delivery system
  16. 16. A Patient Perspective: Patient-centric social media for outcomes and pharmacovigilance considerations Julie Flygare, JD Founder, Project Sleep @REMRunner
  17. 17. Why do patients go online?
  18. 18. What do patients get out of being online?
  19. 19. Social Media v. Real Life
  20. 20. Thank you for your attention!

×